G1_Logo_2022_Reg.png
G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
July 26, 2023 09:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023 16:15 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 06, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1_Logo_2022_Reg.png
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
June 04, 2023 07:13 ET | G1 Therapeutics
- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment - - Trilaciclib Enhances Expression of Genes Associated with Memory T...
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023 16:40 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
May 22, 2023 16:45 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Monica Thomas as its...
G1_Logo_2022_Reg.png
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
May 16, 2023 07:30 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today described recently presented real-world data that...
G1_Logo_2022_Reg.png
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
May 10, 2023 07:31 ET | G1 Therapeutics
- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled...
G1_Logo_2022_Reg.png
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
May 03, 2023 06:30 ET | G1 Therapeutics
- Drove 18% Quarterly Net Revenue Growth of COSELA® (trilaciclib) Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall...
G1_Logo_2022_Reg.png
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2023 17:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1_Logo_2022_Reg.png
G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
April 26, 2023 12:45 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...